Participant group* | Indicator strain;† % of children (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|
44/76–SL | 5/99 | NZ98/254 | M10713 | UKP1.7–2,4 | GB101 | GB355 | GB364 | |
4CMenB 2,4,6,12,40 | ||||||||
After 40-mo booster | 100 (79–100) n = 16 | 100 (78–100) n = 15 | 88 (62–98) n = 16 | 93 (68–100) n = 15 | 100 (78–100) n = 15 | 100 (78–100) n = 15 | 53 (27–79) n = 15 | 93 (68–100) n = 15 |
At 60 mo‡ | 44 (20–70) n = 16 | 88 (62–98) n = 16 | 69 (41–89) n = 16 | 88 (62–98) n = 16 | 81 (54–96) n = 16 | 50 (25–75) n = 16 | 13 (2–38) n = 16 | 81 (54–96) n = 16 |
rMenB 2,4,6,12,40 | ||||||||
After 40-mo booster | 100 (85–100) n = 23 | 100 (85–100) n = 23 | 17 (5–39) n = 23 | 100 (85–100) n = 23 | 74 (52–90) n = 23 | 100 (85–100) n = 23 | 30 (13–53) n = 23 | 78 (56–93) n = 23 |
At 60 mo‡ | 46 (26–67) n = 24 | 83 (61–95) n = 23 | 0 (0–14) n = 24 | 77 (55–92) n = 22 | 29 (13–51) n = 24 | 39 (20–61) n = 23 | 0 (0–15) n = 23 | 59 (36–79) n = 22 |
4CMenB 12,40,42 | ||||||||
After immunization at 42 mo | 100 (48–100) n = 5 | 100 (48–100) n = 5 | 100 (48–100) n = 5 | 100 (48–100) n = 5 | 100 (48–100) n = 5 | 100 48–100) n = 5 | 100 (48–100) n = 5 | 100 (48–100) n = 5 |
At 60 mo‡ | 80 (28–99) n = 5 | 100 (48–100) n = 5 | 80 (28–99) n = 5 | 100 (48–100) n = 5 | 100 (48–100) n = 5 | 100 (48–100) n = 5 | 60 (15–95) n = 5 | 80 (28–99) n = 5 |
rMenB 12,40,42 | ||||||||
After immunization at 42 mo | 100 (75–100) n = 13 | 100 (75–100) n = 13 | 15 (2–45) n = 13 | 83 (52–98) n = 12 | 42 (15–72) n = 12 | 100 (74–100) n = 12 | 8 (0–38) n = 12 | 100 (74–100) n = 12 |
At 60 mo‡ | 85 (55–98) n = 13 | 100 (75–100) n = 13 | 0 (0–25) n = 13 | 92 (62–100) n = 12 | 9 (0–41) n = 11 | 42 (15–72) n = 12 | 9 (0–41) n = 11 | 83 (52–98) n = 12 |
4CMenB 40,42 | ||||||||
After immunization at 40 and 42 mo | 100 (87–100) n = 27 | 100 (87–100) n = 27 | 93 (76–99) n = 27 | 89 (71–98) n = 27 | 92 (75–99) n = 26 | 100 (87–100) n = 26 | 69 (48–86) n = 26 | 100 (87–100) n = 26 |
At 60 mo‡ | 71 (51–87) n = 28 | 100 (88–100) n = 28 | 31 (15–51) n = 29 | 81 (62–94) n = 27 | 44 (25–65) n = 27 | 74 (54–89) n = 27 | 41 (22–61) n = 27 | 81 (62–94) n = 27 |
4CMenB 60,62 | ||||||||
At 60 mo, before immunization | 33 (20–48) n = 46 | 2 (0.055–12) n = 46 | 2 (0.055–12) n = 46 | 83 (69–92) n = 46 | 9 (2–21) n = 46 | 35 (21–50) n = 46 | 2 (0.055–12) n = 46 | 24% (13–39) n = 46 |
After immunization at 60 and 62 mo | 92 (79–98) n = 39 | 100 (91–100) n = 39 | 100 (91–100) n = 39 | 100 (91–100) n = 39 | 100 (91–100) n = 39 | 95 (83–99) n = 39 | 59 (42–74) n = 39 | 97 (87–100) n = 39 |
Note: 4CMenB = multicomponent serogroup B meningococcal vaccine, rMenB = recombinant protein serogroup B meningococcal vaccine, CI = confidence interval.
↵* 4CMenB 2,4,6,12,40 = 4CMenB vaccine administered at 2, 4, 6, 12 and 40 months; rMenB 2,4,6,12,40 = rMenB vaccine administered at 2, 4, 6, 12 and 40 months; 4CMenB 12,40,42 = 4CMenB vaccine administered at 12, 40 and 42 months; rMenB 12,40,42 = rMenB vaccine administered at 12, 40 and 42 months; 4CMenB 40,42 = 4CMenB vaccine administered at 40 and 42 months; 4CMenB 60,62 = 4CMenB vaccine administered to newly recruited vaccine-naive children at 60 and 62 months.
↵† Indicator strains were selected to assess specific antigens, as follows: strain 44/76–SL for factor H binding protein, strain 5/99 for Neiserria adhesin A, NZ98/254 strain for outer membrane vesicle and M10712 strain for Neiserria heparin-binding antigen. The other indicator strains were not matched to vaccine components.
↵‡ The 60-month time point was about 20 months after the final immunization.